Introduction {#Sec1}
============

Lung cancer is a leading cause of cancer-associated death and substantially contributes to the heavy burden worldwide, with a dismal 5-year survival rate of 16.6%^[@CR1]^. Among all primary lung cancers, non-small cell lung cancer (NSCLC) represents approximately 85% of cases. Chemotherapy remains the standard first-line treatment for almost 80% of NSCLC patients, of which platinum-based chemotherapy (PBC) is considered as the most efficacious option, especially for patients with an advanced stage of the disease^[@CR2],\ [@CR3]^. Unfortunately, PBC efficacy varies markedly across individuals. Besides clinical and pathologic features, genetic variation is considered as an important factor to influence the treatment efficacy and prognosis.

For decades, we have witnessed a growing interest in the pharmacogenomics field, and a tremendous amount of epidemiological evidence that gene polymorphisms could give rise to varying drug response has emerged. Many studies have reported the association of genetic factors, including genes related to DNA repair pathway, drug influx and efflux, drug metabolism and detoxification, DNA synthesis, cell cycle control and apoptosis, with PBC response and prognosis of patients^[@CR4]--[@CR8]^. The accumulation of pharmacogenomics findings calls for a more comprehensive systematic review and meta-analysis to summarize the evidence and to identify the general genetic associations among reported results. Some meta-analyses have studied the influences of certain genes on treatment outcomes of NSCLC patients receiving PBC. However, these findings including original studies are not always consistent, and no systematic review and meta-analysis covering all tested polymorphisms has been performed thus far.

The aim of this work is to identify the effects of all eligible genes in clinical prognosis of NSCLC patients receiving platinum-based treatment. A total of 24 single nucleotide polymorphisms (SNPs) of 12 genes (*ERCC1*, *XPA*, *XPC*, *XPD*, *XPG*, *XRCC1*, *XRCC3*, *GSTP1*, *MTHFR*, *RRM1*, *MDR1* and *CDA*) have been studied in our work. The impacts of these genetic variants on PBC efficacy in NSCLC patients were assessed by evaluating the objective response ratio (ORR), progression-free survival (PFS), and overall survival (OS). We think this comprehensive meta-analysis with robust evidence would fill the gap in the pharmacogenomics of platinum in NSCLC patients.

Materials and Methods {#Sec2}
=====================

Search strategy, eligibility criteria and data extraction {#Sec3}
---------------------------------------------------------

We followed the principles proposed by the Human Genome Epidemiology Network (HuGeNet) HuGE Review Handbook of Genetic Association Studies^[@CR9]^.

Relevant studies were searched in PubMed, Chinese National Knowledge Infrastructure (CNKI) and WANFANG databases. A two-step search strategy was implemented and last updated on January 31, 2016. First, the following three groups of keywords were used for searching in MEDLINE (via the PubMed gateway): platinum OR cisplatin OR carboplatin OR oxaliplatin OR nedaplatin, polymorphism OR SNP OR variant, NSCLC OR non-small cell lung cancer. Second, we used different combinations of the above terms for complementary searching. Besides, references cited in the retrieved papers were manually searched in case of missing relevant studies. Afterwards, we singled out the candidate genes that were eligible in our research, and the terms including a candidate gene's official symbol and the three above-mentioned groups of keywords were used to perform a comprehensive search.

The studies included in the meta-analysis had to meet all the following inclusion criteria: (i) cancer should be confirmed as NSCLC; (ii) treatment regimens were platinum-based chemotherapies; (iii) studies provided primary outcomes of interest including ORR, PFS or OS. Studies met any one of the exclusion criteria listed below were excluded in our analysis: (i) studies without indispensable data such as genotypes, overall response rate (ORR), overall survival (OS), or progression-free survival (PFS); (ii) studies with other types of lung cancer such as small cell lung cancer (SCLC) included; (iii) reviews, case reports, and meta-analyses. (iv) studies based on cell lines and animal experiment.

All records were screened by three investigators independently (Tan, Qiu and Jin) with disagreement resolved by discussion. The following information was extracted from each of the eligible studies: first author, publication year, sample size, ethnicity, age, gender, stages of tumor, chemotherapeutic agents, SNPs and genotyping methods, treatment outcomes.

Statistical analysis {#Sec4}
--------------------

We used the ORR as an indicator for PBC efficacy. Patients were classified into two groups: the responding group, which included complete and partial responders (CR and PR), and the non-responding group, which included subjects with stable or progressive diseases (SD and PD)^[@CR10]^. RR and the corresponding 95% CI were used to assess the association between each genetic variant and the response of NSCLC patients treated with PBC. The hazard ratios (HR) and corresponding 95% CI were determined to evaluate OS and PFS. Three genotypic models commonly used in genetic association synopses were applied in this meta-analysis: heterozygous or homozygous variant versus wild type, heterozygous variant versus wild type and homozygous variant versus wild type.

Between-study variance, also known as heterogeneity, was evaluated by the chi-square-based Q test based on chi- square as well as I^2^. Q tests with *P* \> 0.10 were considered with statistical significance. I^2^ described the proportion of variation originating from heterogeneity rather than within-study error, whose value varied from 0 to 100 percent and indicated different heterogeneity degrees. Heterogeneity could be accepted when I^2^ \< 50% (0 \< I^2^ \< 25%: no heterogeneity; 25 \< I^2^ \< 50%: moderate heterogeneity). Sensitivity analysis and subgroup analysis were also applied to find the source of heterogeneity. Pooled RRs and HRs were calculated using the fixed-effects model when the heterogeneity was under the moderate degree or did not exist. Otherwise, the random-effects model was used. Moreover, the potential publication bias was assessed by statistical evaluation with Begg's funnel plot and Egger's linear regression test. The α level of significance was set at 0.05 unless noted otherwise.

In the end, we calculated the false positive report probability (FPRP) of statistically significant results to assess whether the findings were noteworthy^[@CR11]^. The FPRP value was determined based on the P value, the prior probability for the association and statistical power. We set a stringent FPRP threshold of 0.20 and assigned a prior probability range of 0.1--0.001, and the statistical power was based on the ability to detect an OR of 1.5, with α equal to the observed p-value.

All statistical analyses were performed with STATA/SE.12.0 (StataCorp, College station, TX) and R (version 3.2.0, R Foundation for Statistical Computing, Vienna, Austria).

Results {#Sec5}
=======

Characteristics of Eligible Studies {#Sec6}
-----------------------------------

After the process of selection, a total of 111 studies met the inclusion criteria and totally 18,196 NSCLC subjects (between the ages of 51 to 84) who accepted PBC were included in the final meta-analysis. More than 80% of these articles focused on the advanced NSCLC (in disease stages of III--IV). The process of selecting publications is presented in Fig. [1](#Fig1){ref-type="fig"} and more details about the characteristics of the studies included are listed in Table [1](#Tab1){ref-type="table"}.Figure 1Flow diagram of the study selection process for the current meta-analysis. Table 1The baseline characteristics of the studies included in this meta-analysis.First author (Year)Ethnicity (country)Sample sizeMale/femaleMedian ageDisease stageChemotherapeutic drugsOutcomesGenotyping methodSNPsRef.Camps, C. (2003)Caucasian (Spain)3934/564 (27--82)IIIB-IVDDP+GEMORDirect sequencing*XPD* rs1799793 rs13181[@CR12]Ryu, J. S. (2004)Asian (Korea)10988/2160 (32--78)IIIB-IVDDP+TAX/GEM/DOCORSNaPShot assay*ERCC1* rs11615 *XPD* rs1799793 rs13181[@CR13]Gurubhagavatula, S. (2004)Caucasian (USA)10353/5058 (32--77)IIIA-IVDDP/CBP-basedOSPCR-RFLP*XPD* rs1799793 *XRCC1* rs25487[@CR14]Isla, D. (2004)Caucasian (Span)6248/1462 (35--78)IIIB-IVDDP+DOCORTaqMan*ERCC1* rs11615, *XPD* rs13181 rs1799793, *RRM1* rs12806698, *MDR1* rs1045642[@CR15]Zhou, W. (2004)Caucasian (USA)12866/6260 (32--78)IIIA--IVPlatinum basedOSPCR-RFLP*ERCC1* rs11615 rs3212986[@CR16]Wang, Z. H. (2004)Asian (China)10559/4656 (30--74)IIIB--IVDDP/CBP+NVB/TAX/DOCORPCR-RFLP*XECC1* rs1799782[@CR17]Yuan, P. (2005)Asian (China)200130/7056 (30--74)IIIB--IVPlatinum basedORPCR-RFLP*ERCC1* rs3212986, *XPD* rs13181, *XPC* PAT[@CR18]Lu, C. (2006)Caucasian+Mexican/African American425236/198NRIII--IVPlatinum basedOSPCR-RFLP*GSTP1* rs1695[@CR19]de Las, P. R. (2006)Caucasians (Span)135125,1062 (31--81)IIIB- IVDDP+GEMOSTaqMan*ERCC1* rs11615, *XPD* rs1799793, *XRCC1* rs25487[@CR20]Booton, R. (2006)Caucasian (UK)10874/3462.5 (35--80)III--IVDDP/CBP-basedORPCR-RFLP Direct sequencing*XPD* rs13181 rs1799793[@CR21]Yuan, P. (2006)Asian (China)200130/7056 (30‑74)IIIB- IVDDP/CBP+NVB/TAX/DOCORPCR‑RFLP*XRCC1* rs1799782[@CR22]Booton, R. (2006a)Caucasian (UK)10874/3462.5 (35--80)III-IVDDP/CBP-basedOR, OSPCR-RFLP Direct sequencing*GSTP1* rs1695[@CR23]Shi, M. (2006)Asian (China)9767/3060 (22--81)II-IVPlatinum basedORPCR-RFLP*MTHFR* rs1801133[@CR24]Shi, M. (2006a)Asian (China)11281/3160 (22--81)II-IVPlatinum basedORPCR-RFLP*XRCC1* rs25487 rs1799782[@CR25]Su, D. (2007)Asian (China)76179/5158 (28--80)IIIA--IVPlatinum basedORTaqMan*ERCC1* rs11615[@CR26]Sun, X. C. (2007)Asian (China)9662/3458 (34--77)IVDDP/CBP-basedORPCR-cDNA chip*XPA* rs1800975[@CR27]Song, D G. (2007)Asian (China)16697/6956 (30--68)IIIB-IVDDP+NVB/DOC/GEMORPCR-RFLP*XPD* rs1799793[@CR28]Yu, Q Z. (2007)Asian (China)10178/2357 (30--72)III-IVDDP-basedORPCR-RFLP*XPG* rs17655, *MDR1* rs1045642[@CR29]Pan, J. H. (2008)Asian (China)6948/2155 (30--76)IIIB-IVDDP+NVPORPCR-RFLP*MDR1* rs1045642[@CR30]Tibaldi, C. (2008)Caucasian (Italy)6551/1465 (44--77)IIIB--IVDDP+GEMOR, OSTaqMan*ERCC1* rs11615, *XPD* rs13181 rs1799793, *CDA* rs2072671[@CR31]Wu, X. (2008)Caucasian (USA)229135/94NRIIIB--IVCisplatin-basedOSTaqMan*ERCC1* rs3212986, *XPG* rs17655, *GSTP1* rs1695, *MDR1* rs1045642, *XPA* rs1800975, *XPC* rs2228001, *XPC* rs2228000[@CR32]Din, Z H. (2008)Asian (China)11685/3160 (22--81)IIB--IVDDP+GEMORPCR-RFLP*XPD* rs13181[@CR33]Liu, X Z. (2008)Asian (China)5338/1561 (28--74)I-IVDDP/CBP-basedOSTaqMan*XPD* rs13181,[@CR34]Pan, J. H. (2009)Asian (China)5438/1655 (30--76)IIIB-IVDDP+DOCORPCR-RFLP*MDR1* rs1045642[@CR35]Sun, X. (2009)Asian (China)8253/2959 (34--79)IVDDP/CBP-basedOR3D DNA microarray genotyping*XPG* rs1047768 rs17655 *XRCC1* rs25487 rs1799782[@CR36]Feng, J. F. (2009)Asian (China)214158/5659 (21--75)IIB-IVPlatinum-basedORPCR-RFLP*RRM1* rs12806698[@CR37]Feng, J. F. (2009a)Asian (China)11578/3759.6 (34--84)III--IVDDP/CBP-basedORDNA microarray genotyping*XPA* rs1800975[@CR38]Kalikaki, A. (2009)Caucasian (Greece)119101/1861 (39--85)IIIA-IVPlatinum-basedOR, OSPCR-RFLP Direct sequencing*ERCC1* rs3212986, *XPD* rs13181 rs1799793, *GSTP1* rs1695[@CR39]Hong, C. Y. (2009)Asian (China)16499/6561 (27--84)IIIB--IVDDP+NVPORPCR-RFLP*XRCC1* rs25487 rs1799782[@CR40]Gao, C M. (2009)Asian (China)5744/1359 (38--77)II--IVDDP+GEMORPCR-RFLP*XRCC1* rs1799782[@CR41]Hu, S N. (2009)Asian (China)214158/5659 (22--81)II--IVPlatinum basedORPCR-RFLP*RRM1* rs12806698[@CR42]Takenaka, T. (2010)Asian (Japan)12275/4769 (30--86)I--IIIplatinum-basedOSPCR-RFLP Direct sequencing*ERCC1* rs11615 rs3212986[@CR43]Sun, N. (2010)Asian (China)11376/3759.6 (34--84)IIIA-IVDDP/CBP-basedOR3-D polyacrylamide gel-based DNA microarray*GSTP1* rs1695[@CR44]Chen, S. (2010)Asian (China)9576/1958 (35--77)IIIB--IVPlatinum basedORLDR*ERCC1* rs11615, *MDR1* rs1045642[@CR45]Li, F. (2010)Asian (China)11578/3760 (NR)IIIB-IVplatinum-basedOR3-D polyacrylamide gel-based DNA microarray*ERCC1* rs11615 rs3212986*XPD* rs13181[@CR46]Zhou, C. (2010)Asian (China)13074/5661 (30--78)IIIB-IVDDP/CBP+NVB/TAX/GEMORTaqMan*ERCC1* rs11615, *XRCC3* rs861539[@CR47]Zhu, X. L. (2010)Asian (China)9664/3257 (34--79)III-IVDDP/CBP-basedORDNA microarray genotyping*XPC* rs2228001 rs2228000[@CR48]Wang, J. (2010)Asian (China)9063/2755 (33--73)III-IVDDP+NVB/TAX/GEM/DOCORDirect sequencing*ERCC1* rs11615 rs3212986[@CR49]Yuan, P. (2010)Asian (China)199129/7056 (29--74)IIIA-IVplatinum-basedOS, PFSPCR-RFLP*XRCC1* rs25487 rs25489 rs1799782[@CR50]Okuda, K. (2011)Asian (Japan)9073/17NRI-IVplatinum-basedOSPCR-RFLP*ERCC1* rs11615 rs3212986[@CR51]Vinolas, N. (2011)Caucasian (Spain)9479/1561 (37--77)IIIB--IVDDP+NVPOR, OS5′ nuclease allelic discrimination assay*ERCC1* rs11615, *XPD* rs13181 rs1799793, *MDR1* rs1045642, *RRM1* rs12806698[@CR52]Liu, L. (2011)Asian (China)199129/7056 (29--74)IIIA-IVPlatinum-basedOS, PFSPCR--RFLP*XPD* rs13181[@CR53]KimCurran, V. (2011)Asian (China)300201/9960 (33--78)IIIB-IVDDP/CBP+NVB/TAX/GEMORRT-PCR*ERCC1* rs3212986[@CR54]Cui, L. H. (2011)Asian (China)10162/3958 (27--76)IIIB-IVDDP/CBP-basedORRT- PCR*MTHFR* rs1801133[@CR55]Ryu, J. S. (2011)Asian (Korea)298236/6263 (28--89)IIIA-IVDDP+GEM/TAXOSSBE*RRM1* rs12806698[@CR56]Zhou, F. (2011)Asian (China)11167/4457 (42--71)IVDDP/CBP+DOC/GEM/NVB/PEMORDirect sequencing*XRCC1* rs25487, *GSTP1* rs1695[@CR57]Zhai, Y. N. (2011)Asian (China)16398/6561 (27--84)IVDDP+NVBORPCR-RFLP*XPC* rs2228001 rs2228000 PAT[@CR27]Ludovini, V. (2011)Caucasian (Italy)192142/5063 (25--81)IIIB-IVDDP- basedORTaqMan*ERCC1* rs11615 *XPD* rs13181, *XRCC3* rs861539[@CR58]Xu, C. (2011)Asian (China)13090/40NRIIIB-IVPlatinum-basedORPCR-RFLP*XRCC1* rs25487 rs1799782, *XRCC3* rs861539[@CR59]Yan, P. W. (2011)Asian (China)10367/3661 (39--79)IIIB--IVPlatinum-basedORRT-PCR*MDR1* rs1045642[@CR60]Cheng, H. Y. (2011)Asian (China)12082/3858 (34--77)NRDDP/CBP-basedORTwo-color fluorescent probe hybridization*XRCC1* rs25487[@CR61]Jia, X F. (2011)Asian (China)8945/44NRIII-IVDDP/CBP+DOC/GEMORDirect sequencing*XPG* rs1047768, *XPA* rs1800975[@CR62]Li, D R. (2011)Asian (China)8964/2559 (21--84)IIIA-IVDDP-basedORDirect sequencing*XRCC1* rs25487[@CR63]Li, D. R. (2011a)Asian (China)8964/2559 (21--84)IIIA-IVDDP-basedORDirect sequencing*XPD* rs1799793[@CR64]Zhao, W. (2011)Asian (China)15192/5962 (32--82)IIIB-IVDDP/CBP-basedORTaqMan*XRCC1* rs25487[@CR65]Zhou, F. (2011a)Asian (China)9455/3957 (42--71)IIIB-IVDDP-basedORDirect sequencing*XRCC1* rs25487[@CR66]Ren, S. (2012)Asian (China)340232/10860 (30--78)IIIB-IVDDP+NVB/GEM/TAX/DOCOR, OSTaqMan*XPD* rs13181, *RRM1* rs12806698, *XRCC3* rs861539, *XPC* rs2228001 rs2228000[@CR67]Dong, J. (2012)Asian (China)568434/13460 (25--83)III--IVPlatinum basedOSTaqMan*ERCC1* rs11615, *XRCC1* rs25487, *XPC* rs2228000[@CR68]Li, D. (2012)Asian (China)8964/2559 (21--84)III-IVDDP+NVB/TAX, DDP+GEM/DOCORPCR-RFLP*ERCC1* rs11615 *XPD* rs13181, *XRCC1* rs25487[@CR69]Joerger, M. (2012)Caucasian (Netherlands)13777/6059.7 (37--79)IIIB-IVDDP+GEMOR, OS, PFSDNA sequencing*ERCC1* rs11615, *XPD* rs1799793, *RRM1* rs12806698, *CDA* rs2072671, *XRCC3* rs861539[@CR70]Cheng, J. (2012)Asian (China)14289/5362 (43--81)IIIB-IVDDP+NVB/TAXORDirect sequencing*ERCC1* rs11615[@CR71]Li, W. (2012)Asian (China)217148/6959 (24--83)NRPlatinum-basedORPCR-RFLP*GSTP1* rs1695[@CR72]Chen, X. (2012)Asian (China)355248/10760 (32--78)IIIB-IVDDP/CBP-basedORTaqMan*XPD* rs13181, *XRCC3* rs861539[@CR73]Wu, W. (2012)Asian (China)353246/10757 (32--80)III- IVDDP+NVB/TAX/GEM/DOCOR, OSDirect sequencing*XPD* rs13181 rs1052555 rs238406[@CR74]Butkiewicz, D. (2012)Caucasian (Poland)171NRNRI--IVPlatinum basedOS, PFSPCR-RFLP*XPD* rs1799793l, *XRCC3* rs861539[@CR75]Krawczyk, P. (2012)Caucasian (Poland)4333/1063 (NA)IIIB--IVPlatinum basedORPCR-RFLP*ERCC1* rs11615[@CR76]Liao, W. Y. (2012)Asian (Taiwan)6235/2757 (36--78)III- IVDDP+GEMOR, OSTaqMan*ERCC1* rs11615 rs3212986 *XRCC1* rs25487, *XRCC3* rs861539[@CR77]Dogu, G. G. (2012)Caucasian (Turkey)7972/760 (32--84)IB-IVPlatinum basedOSPCR-RFLP*MDR1* rs1045642[@CR78]Ke, H. G. (2012)Asian (China)460334/12655 (32--79)I-IVDDP-basedOSPCR-CTPP*XRCC1* rs25487 rs1799782, *GSTP1* rs1695, *XRCC3* rs861539[@CR79]Lv, H Y. (2012)Asian (China)8549/3656 (36--71)NRDDP+DOC/GEM/NVB/MTAORDirect sequencing*XPG* rs1047768, *GSTP1* rs1695[@CR80]Zhang, Y P. (2012)Asian (China)6238/2458 (37--72)IIIB-IVDDP+NVP/TAX/GEMORTaqMan*GSTP1* rs1695[@CR81]Provencio, M. (2012)Caucasian (Spain)180157/2362 (39--78)IIIB-IVDDP+NVBOR, PFSTaqMan*XRCC3 rs861539*[@CR82]He, C. (2013)Asian (China)228141/8760 (19--84)III-IVDDP/CBP-basedORPCR-RFLP*XPG* rs2296147[@CR83]Hong, W. (2013)Asian (China)13590/4556 (25--72)III-IVDDP/CBP+GEMORTaqMan*ERCC1* rs11615 rs3212986, *MTHFR* rs1801133[@CR84]Liu, H N. (2013)Asian (China)6238/2458 (37--72)NRDDP-basedORTaqman*XRCC1* rs25487[@CR85]Zhao, W. (2013)Asian (China)14792/5560 (32--82)IIIB-IVplatinum-basedOR, OS, PFSTaqMan*XRCC1* rs25487 rs1799782[@CR86]Li, X. D. (2013)Asian (China)496324/17263 (33--79)IIIA-IVplatinum-basedOR, OS, PFSPCR-SBE*XPD* rs13181 rs1799793 rs1052555 rs238406,[@CR87]Li, W. J. (2013)Asian (China)4523/2263 (39--81)IIIB-IVDDP+PEMORTaqman*MTHFR* rs1801133[@CR88]Cheng, H. (2013)Asian (China)11578/3759.6 (34--84)IIIB-IVPlatinum-basedOS, PFS3-D polyacrylamide gel-based DNA*XPD* rs13181, *XPA* rs1800975[@CR89]Zhang, T. (2013)Asian (China)475306/14564 (32--76)III-IVDDP+DOC, DDP/CBP+GEM/NVBOR, OS, PFSTaqMan*XPG* rs1047768 rs17655 rs2296147 rs873601[@CR90]Lee, S. Y. (2013)Asian (Korea)382311/71NRIII-IVDDP+TAXOR, OSSequenome mass spectrometry-based*XPD* rs1052555, *XRCC1* rs25487[@CR91]Mlak, R. (2013)Caucasian (Poland)6243/1961 (38--76)IIIA-IVPlatinum-basedOSPCR-RFLP*RRM1* rs12806698[@CR92]Yuli, Y. (2013)Asian (China)433284/14961 (33--79)IIIA-IVDDP/CBP-basedOS, PFSTaqman*XPG* rs17655[@CR93]Lu, H D. (2013)Asian (China)10054/4661 (41--82)III-IVDDP+NVB/TAXORPCR-RFLP*ERCC1* rs11615[@CR94]Sheng, G F. (2013)Asian (China)6238/2458 (37--72)NRDDP-basedORTaqman*XRCC1* rs25487[@CR95]Yang, W J. (2013)Asian (China)5438/1656 (30--73)III-IVDDP/CBP-basedORPCR-RFLP*XRCC1* rs1799782, *RRM1* rs12806698[@CR96]Zhang, Y P. (2013)Asian (China)6238/2458 (37--72)NRDDP+NVB/TAX/GEM/PEMORDirect sequencing*XPD* rs13181[@CR97]Zhou, G R. (2013)Asian (China)204120/8461 (45--75)NRDDP -basedORMALDI-TOF-MS*XRCC1* rs25487[@CR98]Huang, S. J. (2014)Asian (China)187124/63NRIIIA-IVPlatinum-basedOR, OSMALDI-TOF-MS*ERCC1* rs11615 rs3212986, rs2298881[@CR99]Zhang, L. (2014)Asian (China)375249/126NRIIIA-IVCBP+NVP+DDP, DDP+DOCOR, OS, PFSSequenom MassARRAY platform*XPD* rs13181 rs1799793 rs1052555 rs238406, *XRCC1* rs25487 rs1799782[@CR100]Jin, Z. Y. (2014)Asian (China)378297/8162.4 (36--78)I-IVDDP+GEM/DOC/NVP/TAXOR, OSPCR-RFLP*XPG* rs1047768 rs17655 *XRCC1* rs25489, *XRCC3* rs861539[@CR101]Hu, W. (2014)Asian (China)277184/9363.1 (29--75)IIIA-IVPlatinum-basedOS, PFSPCR-RFLP*XPG* rs1047768 rs17655 rs2296147 rs873601[@CR102]Peng, Y. (2014)Asian (China)235180/5558 (29--84)IIIA-IVDDP+TAX/DOC/GEMOR, OSPCR-CTTP*XRCC1* rs25487[@CR103]Zhou, M. (2014)Asian (China)9356/3761.5 (NR)IIIB-IVDDP+GEMORPCR-RFLP*XPD* rs13181 rs1799793, *CDA* rs2072671[@CR104]Zhao, X. (2014)Asian (China)192132/6060.8 (26--79)IIIA-IVPlatinum-basedOR, OSMALDI-TOF-MS*ERCC1* rs3212986 rs11615 rs2298881[@CR105]Lv, H. (2014)Asian (China)9154/3759 (34--80)IIIB-IVDDP+TAX/GEM/NVPORTaqMan-MGB*GSTP1* rs1695[@CR106]Krawczyk, P. (2014)Caucasian (Poland)11559/5661 (NR)II-IVDDP/CBP+PEMOSHRM, PCR-RFLP*ERCC1* rs11615[@CR107]Sullivan, I. (2014)Caucasian (Spain)161125/3663.7 (36--85)IIIA-IVDDP/CBP-basedOR, OSDynamic array chips*ERCC1* rs3212986 rs11615, *XPD* rs13181 rs1799793, *XPG* rs1047768 rs17655, *XRCC1* rs25487 rs1799782, rs25489, *XPA* rs1800975[@CR108]Dong, C M. (2014)Asian (China)9238/5457 (40--6)IIIB-IVPlatinum-basedORPCR-RFLP*MTHFR* rs1801133[@CR109]Liu, D. (2014)Asian (China)378297/8162.4 (36--78)I-IVDDP+GEM/DOC/NVP/TAXOR, OSPCR-RFLP*XPG* rs1047768 rs17655 *XRCC1* rs25487 rs1799782[@CR110]Kou, G. (2014)Asian (China)5014/3656 (45--78)IIIB-IVDDP+NVPORPCR-RFLP*ERCC1* rs3212986[@CR111]Kalikaki, A. (2015)Caucasian (Greece)10790/1760 (37--78)IIIB-IVDDP/CBP-basedOR, OS, PFSPCR-RFLP*ERCC1* rs3212986, *XRCC1* rs25487[@CR112]Zou, H. Z. (2015)Asian (China)246170/7664.3 (32--76)IIIA-IVDDP/CBP-basedOS, PFSPCR-RFLP*XPG* rs2296147 rs873601[@CR113]Yuan, Z. J. (2015)Asian (China)4742/559 (29--74)III-IVDDP+GEMORDNA sequencing*GSTP1* rs1695[@CR114]Deng, J. H. (2015)Asian (China)9766/3157 (31--79)IIIB-IVDDP+GEM/NVP/TAX/DOCOR, PFSDNA pyrosequencing*XRCC1* rs25487, *GSTP1* rs1695[@CR115]Shi, Z. H. (2015)Asian (China)240155/8561.5 (34--78)III-IVDDP+GEM/NVP/TAX/DOCOR, OSPCR-RFLP*ERCC1* rs11615 rs3212986 rs2298881[@CR116]Han, B. (2015)Asian (China)325116/209NRIIIB-IVDDP+GEM/NVP/TAX/DOCOR, OSPCR-RFLP*XRCC1* rs25487 rs1799782 rs25489, *GSTP1* rs1695[@CR117]Li, P. (2015)Asian (China)14289/5362 (43--81)IIIB-IVDDP+NVPORPCR-RFLP*XPD* rs13181 rs1799793[@CR118]Liu, J. Y. (2015)Asian (China)322226/14062.5 (37--81)IIIB-IVDDP+GEM/NVP/TAX/DOCOR, OSPCR-RFLP*XRCC1* rs25487 rs1799782, *GSTP1* rs1695[@CR119]Wu, G. (2015)Asian (China)282181/101NRIIIA-IVDDP-basedOR, OSPCR-RFLP*GSTP1* rs1695[@CR120]Zhu, M Z. (2015)Asian (China)6840/28NRIIIB-IVDDP/CBP-basedORPCR-RFLP*ERCC1* rs11615[@CR121]NR, no report; DDP, cisplatin; CBP, carboplatin; GEM, gemcitabine; NVP, vinorelbine; PEM, pemetrexed; TAX, taxol/paclitaxel; DOC, docetaxel; LDR, Ligase detection reactions; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; SBE, single base extension; HRM, High Resolution Melt; MALDI-TOF-MS, matrix-assisted laser desorption/ionization time-of flight mass.

Meta-analysis findings {#Sec7}
----------------------

### Genetic variants associated with response to platinum drugs {#Sec8}

As shown in Table [2](#Tab2){ref-type="table"}, we conducted 74 primary meta-analyses and 64 subgroup meta-analyses sorted by ethnicity to study the associations between 24 SNPs of 12 genes and the responses to PBC in NSCLC patients. Of the 138 performed meta-analyses, 26 (19%) resulted in statistically significant (*P* \< 0.05), with the remaining 112 being non-significant. For ORR, RR \< 1 indicated that patients carrying the allele or genotype had a disadvantageous response, RR \> 1 donated that the allele carriers had a favorable response. Pooled RR with 95% CI of individual SNPs identified as statistically associated with favorable responses to PBC were listed as follows: *XRCC1* rs25487 (AA vs. GG: overall RR = 1.27, 95% CI = 1.02--1.58), *XRCC1* rs1799782 (CT vs. CC: overall RR = 1.22, 95% CI = 1.03--1.44; TT vs. CC: overall RR = 1.29, 95% CI = 1.07--1.56; CT+TT vs. CC: overall RR = 1.22, 95% CI = 1.04--1.42), *XRCC3* rs861539 (CT VS CC: Caucasian RR = 1.46, 95% CI = 1.06--1.99 and overall RR = 1.31, 95% CI = 1.07--1.59; TT VS CC: Caucasian RR = 1.59, 95% CI = 1.07--2.36 and overall RR = 1.48, 95% CI = 1.12--1.97; TT+CT VS CC: Caucasian RR = 1.48, 95% CI = 1.10--2.01 and overall RR = 1.28, 95% CI = 1.07--1.52), *XPA* rs1800975 (AG VS AA: Asian RR = 2.17, 95% CI = 1.29--3.64 and overall RR = 1.74, 95% CI = 1.18--2.57), *GSTP1* rs1695 (GG vs. AA: overall RR = 1.45, 95% CI = 1.20--1.74; AG+GG vs. AA: Asian RR = 1.47, 95% CI = 1.11--1.95 and overall RR = 1.37, 95% CI = 1.06--1.76). Pooled RR with 95% CI of individual SNPs identified as statistically associated with unfavorable responses were presented below: *ERCC1* rs3212986 (AA vs. CC: Asian RR = 0.71, 95% CI = 0.54--0.94 and overall RR = 0.72, 95% CI = 0.56--0.94), *XPD* rs13181 (CA+CC vs. AA: Asian RR = 0.83, 95% CI = 0.71--0.98), *XPD* rs1799793 (AA vs. GG: Asian RR = 0.20, 95% CI = 0.05--0.76), *MTHFR* rs1801133 (CT vs. CC: mixed RR = 0.63, 95% CI = 0.44--0.89), *MDR1* rs1045642 (CT vs. CC: Asian RR = 0.69, 95% CI = 0.50--0.95 and overall RR = 0.73, 95% CI = 0.56--0.94; TT vs. CC: Asian RR = 0.47, 95% CI = 0.26--0.85 and overall RR = 0.52, 95% CI = 0.34--0.81; CT+TT vs. CC: Asian RR = 0.61, 95% CI = 0.48--0.79 and overall RR = 0.64, 95% CI = 0.52--0.80).Table 2The association between candidate gene polymorphisms and objective response.Genetic modelSubgroupNo. of StudyEffect modelPooled RR (95%CI)I^2^ (%)P~het~Begg's test (P-value)Egger's test (P-value)*ERCC1* rs3212986  AA VS CCAsian7Fixed0.71 (0.54,0.94)29.20.206Caucasian1Fixed0.85 (0.47,1.53)------Overall8Fixed0.72 (0.56,0.94)18.70.2820.4580.115  CA VS CCAsian7Fixed0.91 (0.78,1.05)46.30.083Caucasian1Fixed1.03 (0.80,1.31)------Overall8Fixed0.92 (0.80,1.05)41.30.1030.3220.259 CA+AA VS CCAsian10Random0.85 (0.68,1.05)58.10.011Caucasian4Random1.19 (0.93,1.51)25.10.261Overall14Random0.95 (0.80,1.13)55.90.0060.4470.441*ERCC1* rs11615  CT VS CCAsian10Random0.87 (0.71,1.08)50.90.032Caucasian6Random0.87 (0.60,1.26)34.70.176Overall16Random0.87 (0.73,1.04)41.80.0400.5280.823  TT VS CCAsian10Random1.04 (0.64,1.69)76.80.000Caucasian6Random0.79 (0.57,1.10)0.00.522Overall16Random0.96 (0.68,1.34)66.70.0001.0000.475 CT+TT VS CCAsian17Random0.83 (0.68,1.02)61.30.000Caucasian8Random0.97 (0.72,1.31)38.50.123Overall25Random0.87 (0.74,1.03)55.00.0010.8150.753*ERCC1* rs2298881  CA VS AAOverall3Fixed0.96 (0.79,1.15)0.00.6370.6020.234  CC VS AAOverall3Fixed0.93 (0.70,1.24)35.20.2140.1170.210 CA+CC VS AAOverall3Fixed0.95 (0.80,1.13)16.50.3020.6020.364 XPA rs1800975  AG VS AAAsian2Random2.17 (1.29,3.64)79.60.027Caucasian1Random1.01 (0.61,1.68)Overall3Random1.74 (1.18,2.57)77.80.0110.1170.156  GG VS AAAsian2Random1.09 (0.59,2.02)85.30.009Caucasian1Random1.22 (0.75,1.99)Overall3Random1.14 (0.74,1.75)71.20.0310.6020.175 AG+GG VS AAAsian3Random1.05 (0.72,1.52)83.80.002Caucasian1Random1.11 (0.68,1.80)Overall4Random1.06 (0.77,1.45)76.00.0060.1740.087 XPC rs2228000  CT VS CCAsian3Fixed1.09 (0.84,1.41)50.60.1320.6020.850  TT VS CCAsian3Fixed1.05 (0.71,1.56)29.10.2440.6020.989 CT+TT VS CCAsian3Fixed1.09 (086,1.40)37.00.2040.1170.030^b^ XPC rs2228001  AC VS AAAsian2Random0.85 (0.58,1.25)88.80.003  CC VS AAAsian2Random0.83 (0.46,1.51)56.10.131 CC+AC VS AAAsian3Random0.90 (0.71,1.14)79.10.0080.6020.065 XPC intron9 PAT  SL VS SSAsian2Fixed0.93 (0.61,1.40)0.00.322  LL VS SSAsian2Random1.07 (0.29,3.94)81.50.020 SL+LL VS SSAsian2Random0.87 (0.38,1.89)70.70.065*XPD* rs13181  AC VS AAAsian8Fixed0.82 (0.65,1.04)9.800.354Caucasian8Fixed1.04 (0.87,1.23)0.00.935Overall16Fixed0.94 (0.81,1.08)0.00.6620.5890.299  CC VS AAAsian2Random1.14 (0.09,14.34)73.60.051Caucasian8Random1.09 (0.87,1.36)0.00.584Overall10Random1.15 (0.88,1.51)26.90.1960.1280.133 CA+CC VS AAAsian11Fixed0.83 (0.71,0.98)0.00.580Caucasian9Fixed1.05 (0.90,1.24)0.00.863Overall20Fixed0.92 (0.82,1.03)0.00.6151.0000.414*XPD* rs1799793  AA VS GGAsian1Random0.20 (0.05,0.76)------Caucasian8Random1.21 (0.96,1.51)0.00.551Overall9Random1.03 (0.69,1.54)52.60.0310.1440.247  GA VS GGAsian4Random0.88 (0.45,1.74)74.60.008Caucasian9Random1.04 (0.87,1.24)0.00.647Overall13Random0.99 (0.81,1.23)35.30.1000.6250.969 GA+AA VS GGAsian6Random0.83 (0.59,1.17)67.30.009Caucasian10Random1.04 (0.89,1.21)0.00.746Overall16Random0.94 (0.79,1.11)40.80.0460.5890.656*XPD* rs1052555  CT+TT VS CCOverall4Random0.92 (0.65,1.31)67.50.0261.0000.813*XPD* rs238406  CA+AA VS CCOverall3Fixed0.96 (0.81,1.15)0.00.6670.1170.007^b^*XPG* rs1047768  CT VS CCAsian3Fixed0.97 (0.79,1.20)18.80.292Caucasian2Fixed1.17 (0.88,1.55)0.00.777Overall5Fixed1.01 (0.85,1.21)0.00.4660.6240.767  TT VS CCAsian3Random0.70 (0.27,1.81)87.90.000Caucasian2Random0.92 (0.64,1.32)0.00.735Overall5Random0.80 (0.49,1.32)76.20.0020.1420.155 CT+TT VS CCAsian5Random0.86 (0.61,1.21)68.30.013Caucasian2Random1.07 (0.84,1.37)0.00.890Overall7Random0.94(0.75,1.19)55.60.0360.2930.319*XPG* rs17655  CG VS CCAsian6Fixed1.09 (0.92,1.27)22.60.264Caucasian1Fixed1.00 (0.58,1.72)------Overall7Fixed1.08 (0.93,1.26)8.20.3660.4530.230  GG VS CCAsian6Fixed1.20 (0.99,1.45)20.10.282Caucasian1Fixed1.16 (0.71,1.88)------Overall7Fixed1.19 (0.99,1.43)4.50.3920.6520.417 CG+GG VS CCAsian6Fixed1.12 (0.97,1.29)38.10.152Caucasian1Fixed1.11 (0.68,1.80)------Overall7Fixed1.12 (0.97,1.29)25.70.2330.6520.495*XPG* rs2296147  CT VS CCOverall2Fixed1.14 (0.84,1.54)0.00.477  TT VS CCOverall2Fixed1.34 (0.92,1.97)0.00.547 CT+TT VS CCOverall2Fixed1.22 (0.96,1.56)0.00.863*XRCC1* rs25487  GA VS GGOverall15Random1.08 (0.94,1.24)60.80.0010.4580.375  AA VS GGOverall15Random1.27 (1.02,1.58)66.70.0000.2160.095 GA+AA VS GGOverall23Random0.89 (0.76,1.05)78.50.0000.013^a^0.004^b^*XRCC1* rs1799782  CT VS CCOverall13Random1.22 (1.03,1.44)63.40.0010.0510.032^b^  TT VS CCOverall13Random1.29 (1.07,1.56)50.50.0191.0000.735 CT+TT VS CCOverall14Random1.22 (1.04,1.42)65.10.0000.1390.082*XRCC1* rs25489  GA VS GGOverall2Fixed0.99 (0.81,1.22)0.00.801  AA VS GGOverall2Fixed0.96 (0.76,1.22)0.00.712 XRCC3 rs861539  CT VS CCAsian3Fixed1.20 (0.94,1.53)0.00.588Caucasian3Fixed1.46 (1.06,1.99)26.30.257Overall6Fixed1.31 (1.07,1.59)0.00.5020.005^a^0.009^b^  TT VS CCAsian1Fixed1.36 (0.91,2.02)Caucasian3Fixed1.59 (1.07,2.36)0.00.935Overall4Fixed1.48 (1.12,1.97)0.00.9210.04^a^0.001^b^ TT+CT VS CCAsian5Fixed1.16 (0.94,1.44)0.00.764Caucasian3Fixed1.48 (1.10,2.01)0.00.472Overall8Fixed1.28 (1.07,1.52)0.00.7230.001^a^0.000^b^*RRM1* rs12806698  AA VS CCOverall4Fixed0.61 (0.33,1.12)0.00.9270.7340.434  CA VS CCOverall6Fixed1.02 (0.86,1.21)0.00.9441.0000.765 CA+AA VS CCOverall6Fixed0.98 (0.83,1.16)0.00.9541.0000.770*MTHFR* rs1801133  CT VS CCOverall5Fixed0.63 (0.44,0.89)41.00.148'0.3270.297  TT VS CCOverall5Random0.81 (0.38,1.74)64.00.0250.3270.392 CT + TT VS CCOverall5Random0.66 (0.37,1.18)64.80.0230.6240.598*GSTP1* rs1695  AG VS AAAsian5Random1.19 (0.92,1.54)73.80.004Caucasian2Random0.94 (0.62,1.44)0.00.529Overall7Random1.14 (0.91,1.41)63.10.0120.8810.891  GG VS AAAsian4Random1.17 (0.71,1.91)78.50.001Caucasian2Random0.73 (0.28,1.90)------Overall5Fixed1.45 (1.20,1.74)0.00.4161.0000.654 AG+GG VS AAAsian11Random1.47 (1.11,1.95)81.10.000Caucasian2Random0.90 (0.59,1.36)0.00.713Overall13Random1.37 (1.06,1.76)78.00.0000.6250.283*MDR1* rs1045642  CT VS CCAsian3Fixed0.69 (0.50,0.95)0.00.495Caucasian2Fixed0.81 (0.52,1.26)0.00.421Overall5Fixed0.73 (0.56,0.94)0.00.6780.6240.610  TT VS CCAsian3Fixed0.47 (0.26,0.85)27.40.252Caucasian2Fixed0.62 (0.32,1.17)0.00.939Overall5Fixed0.52 (0.34,0.81)0.00.6210.1420.226 CT+TT VS CCAsian5Fixed0.61 (0.48,0.79)0.00.590Caucasian2Fixed0.75 (0.49,1.14)0.00.551Overall7Fixed0.64 (0.52,0.80)0.00.7220.6520.739 CDA rs2072671  AC VS AAAsian1Fixed1.48 (0.78,2.81)Caucasian2Fixed0.85 (0.56,1.30)43.70.183Overall3Fixed0.99 (0.70,1.40)48.60.1430.6020.829  CC VS AACaucasian2Random0.62 (0.10,3.96)70.80.065 AC+CC VS AAAsian1Random1,48 (0.78,2.81)70.60.064Caucasian2Random0.77 (0.36,1.64)Overall3Random0.95 (0.53,1.71)65.60.0550.6020.802^a^Begg's test *P* \< 0.05; ^b^Egger's test *P* \< 0.05.

### Genetic variants associated with OS and PFS {#Sec9}

Statistically significant results with HR \> 1 indicated that patients carrying the allele or genotype harbored a poorer OS or PFS, while with HR \< 1 meant better OS or PFS of patients. As for OS (Table [3](#Tab3){ref-type="table"}), 52 meta-analyses were preformed to examine the influence of 22 SNPs in 11 genes on the overall survival. Seven results were identified as statistically significantly associated with OS. Of them, *ERCC1* rs11615 (CT+TT vs. CC: HR = 1.47, 95% CI = 1.15--1.88), *ERCC1* rs3212986 (AA vs. CC: HR = 2.06, 95% CI = 1.19--3.57), *XPD* rs13181 (AC+CC vs. AA: HR = 1.24, 95% CI = 1.07--1.44), and *XPD* rs1052555 (CT+TT vs. CC: HR = 1.71, 95% CI = 1.31--2.23) might be related to a poorer OS, while *XPG* rs873601 (GG vs. AA: HR = 0.67, 95% CI = 0.46--0.97), *XPG* rs2296147 (TT vs. CC: HR = 0.40, 95% CI = 0.27--0.61), and *XPD* rs1799793 (GA vs. GG: HR = 0.78, 95% CI = 0.62--0.99) might be potentially related to a better OS. No significant association was identified in the remaining SNPs. As for PFS (Table [4](#Tab4){ref-type="table"}), 19 meta-analyses were conducted and 11 SNPs of 4 genes were investigated to explore their associations with the PFS of NSCLL patients. Our findings showed that patients with C allele of *XPD* rs13181 had a poorer PFS (AC+CC vs. AA: HR = 1.38, 95% CI = 1.10--1.73), and the T allele of *XPD* rs1052555 also indicated a poorer PFS (CT+TT vs. CC: HR = 1.97, 95% CI = 1.38--2.83).Table 3The association between candidate gene polymorphisms and OS.Genetic modelNo. of StudyEffect modelPooled HR (95%CI)I2%P~het~Begg's test (P-value)Egger's test (P-value)*ERCC1* rs3212986  AA VS CC4Fixed2.06 (1.19,3.57)49.90.1120.1740.270  CA VS CC5Fixed1.16 (0.83,1.63)16.50.3100.3270.622 CA+AA VS CC6Random0.97 (0.63,1.50)81.10.0000.8510.356*ERCC1* rs11615  CT VS CC6Fixed1.10 (0.89,1.37)0.00.4260.5730.251  TT VS CC8Random1.40 (0.92,2.16)60.10.0141.0000.796 CT+TT VS CC5Fixed1.47 (1.15,1.88)0.00.6820.6240.597*ERCC1* rs2298881 AC VS AA3Fixed1.20 (0.81,1.79)0.00.5260.6020.644 CC VS AA3Fixed1.20 (0.66,2.18)0.00.4370.1170.151 XPA rs1800975 AG+GG VS AA2Random0.97 (0.73,1.29)85.30.009 XPC rs2228000  CT VS CC2Random0.74 (0.37,1.48)85.50.009  TT VS CC2Fixed0.91 (0.56,1.50)00.449 CT+TT VS CCRandom0.77 (0.40,1.48)84.90.010 XPC rs2228001 CC+AC VS AA2Fixed0.94 (0.74,1.20)0.00.514*XPD* rs13181 AC+CC VS AA8Fixed1.24 (1.07,1.44)7.700.3710.4580.645 *XPD* rs1799793  AA VS GG5Random1.09 (0.62,1.92)65.30.0210.6240.595  GA VS GG4Fixed0.78 (0.62,0.99)0.00.4190.4970.422 GA+AA VS GG6Random1.29 (0.94,1.76)66.90.0100.8510.759*XPD* rs1052555 CT+TT VS CC3Fixed1.71(1.31,2.23)0.0.00.816*XPD* rs238406 CA+AA VS CC2Fixed1.26 (0.95,1.68)0.00.913*XPG* rs1047768  CT VS CC2Random1.11(0.69,1.79)59.30.117  TT VS CC3Random1.11 (0.45,2.78)89.90.000.6020.326*XPG* rs17655  CG VS CC2Fixed0.98 (0.73,1.32)0.00.743  GG VS CC2Fixed1.02 (0.68,1.51)0.00.394 CG+GG VS CC2Fixed0.86 (0.68,1.08)19.40.265*XPG* rs2296147  CT VS CC3Fixed0.79 (0.59,1.05)0.00.9200.6020.376  TT VS CC3Fixed0.40(0.27,0.61)13.30.3150.1170.333*XPG* rs873601  AG VS AA3Fixed0.91 (0.69,1.21)0.00.5481.0000.878  GG VS AA3Fixed0.67 (0.46,0.97)0.50.3660.6020.710*XRCC1* rs25487  GA VS GG13Random0.87 (0.71,1.07)70.30.0000.038^a^0.029^b^  AA VS GG11Random0.84 (0.52,1.36)80.10.0000.1860.183 GA+AA VS GG6Random0.96(0.68,1.36)68.80.0070.039^a^0.019^b^*XRCC1* rs1799782  CT VS CC7Fixed0.91 (0.76,1.08)0.00.7840.3620.233  TT VS CC7Fixed0.81 (0.63,1.04)0.00.4240.4530.685*XRCC1* rs25489  GA VS GG2Fixed0.85 (0.63,1.15)41.30.192  AA VS GG2Fixed1.31 (0.65,2.65)22.60.256 XRCC3 rs861539  CT VS CC3Fixed0.95 (0.76,1.17)0.00.6300.1170.064  TT VS CC3Fixed1.01 (0.72,1.41)46.10.1560.6020.935 TT+CT VS CC2Fixed0.83 (0.61,1.13)0.00.661*RRM1* rs12806698  AA VS CC2Fixed0.86 (0.47,1.58)0.00.977  AC VS CC2Fixed0.91 (0.66,1.24)0.00.513 AC+AA VS CC4Random1.01 (0.71,1.42)66.70.0290.1740.391*GSTP1* rs1695  AG VS AA8Random1.03 (0.82,1.28)52.90.0380.3830.113  GG VS AA5Random0.87(0.51,1.47)71.20.0080.6240.535 AG+GG VS AA2Fixed1.19 (0.92,1.55)0.00.538*MDR1* rs1045642  CT VS CC3Fixed0.91 (0.66,1.25)38.50.1960.6020.366  TT VS CC3Fixed0.91 (0.64,1.29)0.00.8830.1170.173 CDA rs2072671  AC VS AA2Fixed0.90 (0.63,1.29)0.00.334  CC VS AA2Random1.80 (0.47,6.87)80.60.023^a^Begg's test *P* \< 0.05; ^b^Egger's test *P* \< 0.05. Table 4The association between candidate gene polymorphisms and PFS.Genetic modelNo. of StudyEffect modelPooled HR (95%CI)I2%P~het~Begg's test (P-value)Egger's test (P-value)*XRCC1* rs25487  GA VS GG3Fixed0.91 (0.71,1.17)0.00.3760.6020.273  AA VS GG3Fixed0.72 (0.48,1.08)29.20.2430.6020.571 GA+AA VS GG5Fixed0.86 (0.72,1.05)0.000.7740.0500.008^b^*XRCC1* rs1799782  CT VS CC3Fixed1.06 (0.82,1.36)0.00.7770.1170.461  TT VS CC3Fixed1.00 (0.67,1.50)8.80.3340.1170.429 CT+TT VS CC3Fixed1.05 (0.83,1.34)0.00.6410.1170.401XRCC3 rs 86153 CT VS CC3Fixed0.86 (0.70,1.06)0.00.8950.2210.562 **TT VS CC**3Fixed0.94 (0.66,1.33)0.00.3720.1170.166*XPD* rs13181 AC+CC VS AA4Fixed1.38 (1.10,1.73)0.00.9650.042^a^0.029^b^*XPD* rs1799793 GA+AA VS GG4Fixed1.07 (0.86,1.33)0.00.6580.042^a^0.013^b^*XPD* rs1052555 CT+TT VS CC2Fixed1.97 (1.38,2.83)0.00.815*XPD* rs238406 CA+AA VS CC2Fixed1.27 (0.89,1.81)0.00.864*XPG* rs1047768 CT VS CC2Fixed1.08 (0.79,1.48)17.70.270*XPG*rs17655 CG VS CC3Fixed0.85 (0.65,1.12)0.00.5550.6020.242 GG VS CC3Fixed0.69 (0.48,0.99)0.00.9740.1170.077*XPG* rs2296147 CT VS CC3Fixed0.80 (0.60,1.08)0.00.5030.6020.353 TT VS CC3Fixed0.51 (0.33,0.78)17.80.2960.6020.455*XPG* rs873601 AG VS AA3Fixed0.84 (0.63,1.13)0.00.8760.6020.678 GG VS AA3Fixed0.62 (0.41,0.91)0.00.8020.6020.992^a^Begg's test *P* \< 0.05; ^b^Egger's test *P* \< 0.05.

### Heterogeneity and publication bias {#Sec10}

A total of 54% (n = 97) of meta-analyses showed no heterogeneity (I^2^: 0 to 25%) and 14% (n = 25) presented moderate heterogeneity (I^2^: 25 to 50%), and large heterogeneity even extreme heterogeneity existed in other meta-analyses. Sensitivity analysis and subgroup analysis were also applied to find the source of heterogeneity. The clinical heterogeneity such as disease stages, different chemotherapy regimens might be the major reason for the large or extreme heterogeneity.

We used *P* value for Egger's test to evaluate the potential publication bias. Our results suggested that effects of *XPD* rs238406 (CA+AA vs. CC), *XRCC1* rs25487 (GA+AA vs. GG), *XRCC1* rs1799782 (CT vs. CC) and *XRCC3* rs861539 (CT vs. CC, TT vs. CC and TT+CT vs. CC) on the ORR had significant publication bias. There was also some publication bias in analysis of the effects of *XRCC1* rs25487 (GA vs. GG, GA+AA vs. GG) on the OS. Three meta-analyses showed bias in the association of certain SNPs with PFS, including *XPD* rs13181 (AC+CC vs. AA), *XPD* rs1799793 (GA+AA vs. GG) and *XRCC1* rs25487 (GA+AA vs. GG). More details were listed in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.

### False positive report probability {#Sec11}

False positive findings regarding associations between genetic variants and diseases lead to a confounding effect. Here we assessed the FPRP to determine whether our finding was noteworthy. As shown in Table [5](#Tab5){ref-type="table"}, 23 out of 35 results had FPRP lower than 0.2, with the prior probability set as 0.1 and the cut-off FPRP value as 0.2. The details of significant associations characterized by assessing FPRP are reported in Table [5](#Tab5){ref-type="table"}.Table 5FPRP values for the SNPs associated with the response, OS and PFS of NSCLC patients receiving platinum-based chemotherapy.Genetic/SNPGenetic modelSubgroupNo. of studyPooled RR of ORR(95% CI)Reported P-valuePowerFPRP based on prior0.10.010.001*ERCC1* rs3212986AA VS CCAsian70.71(0.54,0.94)0.0170.6700.184^\#^0.7120.961AA VS CCOverall80.72(0.56,0.94)0.0160.7140.166^\#^0.6860.957XRCC3 rs861539CT VS CCCaucasian31.46(1.06,1.99)0.0170.5680.2080.7430.967CT VS CCOverall61.31(1.07,1.59)0.0060.9150.058^\#^0.4050.873TT VS CCCaucasian31.59(1.07,2.36)0.0210.3860.3320.8460.982TT VS CCOverall41.48(1.12,1.97)0.0070.5370.108^\#^0.5710.931TT+CT VS CCCaucasian31.48(1.10,2.01)0.0120.5340.169^\#^0.6910.958TT+CT VS CCOverall81.28(1.07,1.52)0.0050.9650.043^\#^0.3330.835XPA rs1800975AG VS AAAsian22.17(1.29,3.64)0.0030.0810.2700.8030.976AG VS AAOverall31.74(1.18,2.57)0.0050.2280.175^\#^0.7000.959*XPD* rs13181CA+CC VS AAAsian110.83(0.71,0.98)0.0280.9950.2020.7350.966*XPD* rs1799793AA VS GGAsian10.20(0.05,0.76)0.0470.0690.8610.9850.999*XRCC1* rs25487AA VS GGOverall151.27(1.02,1.58)0.0320.9320.2360.7720.972*XRCC1* rs1799782CT VS CCOverall131.22(1.03,1.44)0.0190.9930.145^\#^0.6510.950TT VS CCOverall131.29(1.07,1.56)0.0090.9400.076^\#^0.4760.902CT+TT VS CCOverall141.22(1.04,1.42)0.0100.9960.085^\#^0.5050.911*MTHFR* rs1801133CT VS CCOverall50.63(0.44,0.89)0.0090.3740.174^\#^0.6990.959*GSTP1* rs1695GG VS AAOverall51.45(1.20,1.74)0.0000.6420.001^\#^0.010^\#^0.092^\#^*GSTP1* rs1695AG+GG VS AAAsian111.47(1.11,1.95)0.0080.5560.109^\#^0.5730.931Overall131.37(1.06,1.76)0.0140.7610.140^\#^0.6420.948*MDR1* rs1045642CT VS CCAsian30.69(0.50,0.95)0.0230.5840.2610.7960.975Overall50.73(0.56,0.94)0.0150.7590.148^\#^0.6570.951TT VS CCAsian30.47(0.26,0.85)0.0130.1240.4760.9090.990Overall50.52(0.34,0.81)0.0040.1360.2020.7360.966CT+TT VS CCAsian50.61(0.48,0.79)0.0000.2500.006^\#^0.066^\#^0.417Overall70.64(0.52,0.80)0.0000.3600.002^\#^0.024^\#^0.197^\#^*ERCC1* rs11615CT+TT VS CCOverall51.47(1.15,1.88)0.0020.5640.033^\#^0.2740.792*ERCC1* rs3212986AA VS CCOverall42.06(1.19,3.57)0.0100.1290.4110.8850.987*XPD* rs13181AC+CC VS AAOverall81.24(1.07,1.44)0.0050.9940.042^\#^0.3240.829*XPD* rs1799793GA VS GGOverall40.78(0.62,0.99)0.0410.9020.2910.8190.979*XPD* rs1052555CT+TT VS CCOverall31.71(1.31,2.23)0.0000.1670.004^\#^0.043^\#^0.310*XPG* rs873601GG VS AAOverall30.67(0.46,0.97)0.0340.5110.3740.8680.985*XPG* rs2296147TT VS CCOverall30.40(0.27,0.61)0.0000.0090.021^\#^0.189^\#^0.702*XPD* rs13181AC+CC VS AAOverall41.38(1.10,1.73)0.0050.7650.058^\#^0.4030.872*XPD* rs1052555CT+TT VS CCOverall21.97(1.38,2.83)0.0000.0700.030^\#^0.2560.776^\#^FPRP value \<0.2.

High-quality significant associations that emerged from the current meta-analysis were discussed below.

### Excision Repairs Cross-complementation Groups 1 (*ERCC1*) {#Sec12}

Data showed that *ERCC1* rs3212986 (C8092A) variant was related to the treatment response to PBC, and A allele may have poorer response comparing with C allele in Asians (AA vs. CC: pooled OR = 0.71, 95% CI = 0.54--0.94). Only moderate between-study heterogeneity was observed (I^2^ = 29.2%), and with a low FPRP when prior probability level was set as 0.1, suggesting that A allele of *ERCC1* rs3212986 might be specifically linked to the poorer response in Asians.

*ERCC1* rs11615 (C354T) was associated with OS, and T allele carriers might have unfavorable OS with HR being 1.47 and corresponding 95% CI being 1.15--1.88, and with no heterogeneity and low FPRP when prior probability level was set as 0.1, but subgroup classification by ethnicity were not performed.

### Xeroderma Pigmentosum Group D (*XPD*) {#Sec13}

Only the dominant model was used to analyze the relation between *XPD* rs13181 (A2251C) mutation and OS due to insufficient raw data. We found that the variant C allele was remarkably associated with the adverse OS in overall NSCLC patients treated with PBC (AC+CC vs. AA: HR = 1.24, 95% CI = 1.07--1.44). There was no heterogeneity and publication bias in the meta-analysis, and FPRP was low with the prior probability level being 0.1. C allele was also related to poor PFS with low FPRP at the high prior probability levels (AC+CC vs. AA: HR = 1.38, 95% CI = 1.10--1.73). No heterogeneity with statistical significance was observed, but the *P* value for Egger's test showed that there was some publication bias in the meta-analysis. These results indicated that C allele was a risk allele for the poor clinical prognosis of NSCLC patients.

For other SNPs (rs1052555, C2133T) of *XPD*, we found that T allele was a risk allele and might be significantly associated with unfavorable OS (CT+TT vs. CC: HR = 1.71, 95% CI = 1.31--2.23). In the beginning, we included 4 articles in the meta-analysis and found that extreme heterogeneity and publication bias existed. After sensitivity analysis, we removed one article that was identified as the major source of heterogeneity, then I^2^ reduced to zero and no bias was observed from these data. The report had low FRPR with the prior probability level being 0.1 or 0.01. T allele was also related to poor PFS, and pooled HR was 1.97 and the 95% CI ranged from 1.38 to 2.83, though the report had low FPRP at high prior probability levels and no heterogeneity was observed. Further investigation with a larger sample size is needed to confirm the association between rs1052555 variant and prognosis of NSCLC patients.

### Xeroderma Pigmentosum Group G (*XPG*) {#Sec14}

*XPG* rs2296147 (T242C) might be associated with NSCLC patients' prognosis receiving platinum drugs. We found that T allele acted as a protective allele with the carriers having favorable OS (TT vs. CC: HR = 0.40, 95% CI = 0.27--0.61), no heterogeneity and publication bias was detected, and the FPRP was low both at the high (0.1) and intermediate (0.01) prior probability levels. The strength of association needs to be further studied because of the small sample size of current meta-analysis.

### X-Ray Cross-Complementing Group 1 (*XRCC1*) {#Sec15}

Three genetic models were used to analyze the association between *XRCC1* rs1799782 (C580T) polymorphisms and ORR, and results confirmed the positive response of patients carrying T allele to PBC with a low FPRP at the high (0.1) prior probability level, but large between-study heterogeneity existed in the three meta-analyses ((CT vs. CC: HR = 1.22, 95% CI = 1.03--1.44, I^2^: 63.4%); (TT vs. CC: HR = 1.29, 95% CI = 1.07--1.56, I^2^: 50.5%); (CT+TT vs. CC: HR = 1.22, 95% CI = 1.04--1.42, I^2^: 65.1%)).

### X-Ray Cross-Complementing Group 3 (*XRCC3*) {#Sec16}

Results from subgroup meta-analysis sorted by ethnicity showed that T allele of *XRCC1* rs861539 (C241T) was associated with the positive response of PBC treatment in Caucasian population, three genetic models had consistent results (CT VS CC: RR = 1.46, 95% CI = 1.06--1.99; TT VS CC: RR = 1.59, 95% CI = 1.07--2.36; TT+CC VS CC: RR = 1.48, 95% CI = 1.10--2.01), no heterogeneity has been found. Begg's test and Egger's test revealed that some publication bias existed in the meta-analysis. However, Lower FRPR values suggested that the findings were statistically significant. Genetic variant of *XRCC1* rs861539 was not associated with OS and PFS in the current meta-analysis.

### Methylenetetrahydrofolate Reductase (*MTHFR*) {#Sec17}

T allele of *MTHFR* rs1801133 (C665T) might be related to the negative response, the report had low FPRP at the high (0.1) prior probability level, with pooled HR = 0.63, 95% CI = 0.44--0.89, I^2^ = 41.0% when comparing CT and CC genotypes. The other genetic models including TT vs. CC and CT+TT vs. CC didn't show statistical significance.

### Glutathione S-transferase P1 (*GSTP1*) {#Sec18}

For *GSTP1* rs1695 (A313G), two genetic models showed consistent results about the association of the SNP with response (GG vs. AA: HR = 1.45, 95% CI = 1.20--1.74; AG+GG vs. AA: HR = 1.37, 95% CI = 1.06--1.76), the same effects were also observed in the Asian group by subgroup analysis in model AG+GG vs. AA (HR = 1.47, 95% CI = 1.11--1.95). However, we did not find a significant association in model AG vs. AA, low frequency of G allele and an insufficient sample size might be a major reason for it. We further assessed the FPRP value, and data showed low FPRP with probability level being 0.1. These results suggested that the G allele might play a protective role in the response of platinum-based treatment.

### Multidrug resistance 1 (*MDR1*) {#Sec19}

There were statistically significant associations between *MDR1* rs1045642 (T3435C) polymorphism and treatment response in both overall and Asian groups in three comparison genetic models (CT vs. CC, TT vs. CC, CT+TT vs. CC), and results are presented in Table [2](#Tab2){ref-type="table"}. Three statistically significant findings with low FPRP were considered as noteworthy (CT vs. CC: overall RR = 0.73, 95% CI = 0.56--0.94; CT+TT vs. CC: Asian RR = 0.61, 95% CI = 0.48--0.79; CT+TT vs. CC: overall RR = 0.64, 95% CI = 0.52--0.80). Significant between-study heterogeneity and potential bias were not observed in all comparison models.

### Biological pathways associated with platinum drugs treatment outcomes in NSCLC patients {#Sec20}

Genetic variants significantly associated with treatment outcomes of NSCLC patients receiving PBC had impacts on several biological pathways or certain physiological functions. As shown in Fig. [2](#Fig2){ref-type="fig"}, they included DNA repair pathway (*EXCC1*, *XPD*, *XPG* and *XRCC1*), drug influx and efflux (*MDR1*), metabolism and detoxification (*GSTP1*) and DNA synthesis (*MTHFR*).Figure 2Biological pathways and physiological functions influenced by genetic variants which were statistically significantly associated with clinical outcomes of platinum-based chemotherapy in NSCLC patients.

Discussion {#Sec21}
==========

In this study, we described the meta-analysis findings of associations between genetic polymorphisms and treatment outcomes of NSCLC patients receiving platinum drugs. Our study identified that 14 SNPs in 10 genes were statistically associated with clinical prognosis including treatment response, OS and PFS. We further calculated FPRPs of the statistically significant results and 23 results were identified with high-quality evidence (Table [5](#Tab5){ref-type="table"}).

The anti-cancer activity of platinum agents mainly depends on the formation of DNA adducts which inhibit DNA replication, hinder cell division and induce cell apoptosis^[@CR11]^. DNA repair pathways including nucleotide excision repair (NER) and base excision repair (BER) could timely repair the damaged DNA induced by platinum agents and thus lead to treatment failure^[@CR122]^. *ERCC1*, *XPA*, *XPC*, *XPD* and *XPG* are important components of NER. Being consistent with the studies by Yang *et al*.^[@CR123]^ and Xu *et al*.^[@CR124]^, our results confirmed the association between T allele of *ERCC1* rs11615 and shorter OS. In addition, we found that A allele of *ERCC1* rs3212986 was a risk allele that could shorten the carriers' OS and decrease the activity of platinum, while some previously published meta-analyses did not report this effect^[@CR124]--[@CR127]^. However, the association should be replicated in other subsequent studies. In the present meta-analysis, we firstly assessed the influence of *ERCC1* rs2298881 variant, but no significant association was found. We studied four SNPs of XPD in this work and found that XPD rs13181, a common SNP of XP*D*, was closely related to reduced OS and PFS. For the other SNP (rs1052555) of *XPD*, we found that T allele was a risk allele and might significantly associate with unfavorable OS and PFS. This is the first meta-analysis to assess the *XPD* rs1052555 variant, and the robust association needs to be further confirmed by subsequent studies with larger sample sizes. For *XPG*, we found that rs2296147 might be related to patients' OS, and T allele could indicate a favorable OS. The other three SNPs of *XPG* (rs1047768, rs17655 and rs873601) showed no significant association with the ORR, OS and PFS. *XRCC1* is a limiting factor in the base excision repair (BER) pathway. Our results and the previous studies confirmed the positive role of rs1799782 T allele in response to PBC^[@CR128]--[@CR130]^. For rs25487 of *XRCC1*, the statistically significant association between rs25487 polymorphism and ORR deserves to be further studied due to the high FRPR. *XRCC3* is also important for DNA repair, Qiu *et al*. previously reported that *XRCC3* rs861539 variation was related to good response of platinum treatment but not to survival, the same result was shown from the present meta-analysis. The *MTHFR* gene encodes an enzyme that is a central regulator for folate metabolism. It is suggested that *MTHFR* mutation was associated with increased risk of cardiovascular diseases and cancer^[@CR131]^. We identified that the T allele was related to a negative response of PBC. *MDR1* gene encodes for P-glycoprotein (P-gp), which plays a major role in the process of drug efflux and influx across the cell membrane^[@CR132]^. We found that *MDR1* rs1045642 variant was associated with ORR only in Asians, and published meta-analyses supported the association^[@CR133],\ [@CR134]^. GST is a phase II metabolic enzyme involved in the platinum detoxification, mediated by glutathione (GSH) conjugation^[@CR123]^. Increasing GSH content would decrease platinum-DNA binding and result in platinum resistance. *GSTP1* gene was found to be associated with platinum treatment response, and our results indicated that T allele of *GSTP1* rs1695 increased the ORR in NSCLL patients, but the association was only observed in Asians. A previous meta-analysis also reported the same effect as ours^[@CR123]^.

Great efforts have been made to identify the molecular predictive markers of platinum sensitivity. By further integrating our results according to genes biological functions, we found that the majority of polymorphisms of those genes significantly associated with treatment outcomes of platinum agents were involved in four biological pathways or physiological functions. According to the mechanism of platinum, DNA repair pathway may play a key role in the response of platinum therapy. Our results showed that the important components of DNA repair pathways (*ERCC1*, *XPD*, *XPG*, *XRCC1* and *XRCC3*) were involved in the efficacy of platinum treatment and clinical outcome of NSCLL patients. *MDR1* and *GSTP1*, which were related to drug transportation and detoxification respectively, influenced the outcome of platinum treatment. Another potential key gene was *MTHFR*, which was involved in regulating folate metabolism and DNA synthesis and was correlated with platinum sensitivity.

In the current meta-analysis, we comprehensively searched the relevant articles and explored all the eligible genes related to multiple biological functions, aiming to provide an updated and more critical summary of the available evidence of genetic polymorphisms and treatment outcomes of PBC in NSCLC patients. We first analyzed six SNPs including *ERCC1* rs2298881, *XPD* rs1052555, *XPD* rs238406, *XPG* rs17655, *XPG* rs2296147 and *XPG* rs873601. There is a high chance that an initial "statistically significant" finding based on *P* value alone turns out to be a false-positive finding, so we calculated the FPRP of each statistically significant association to ensure the credibility of our findings, and we identified 11 SNPs in 9 genes that might truly associate with the ORR and/or OS and/or PFS of NSCLC patients receiving platinum drugs.

However, there were some limits in the present meta-analysis. First, despite the intensive efforts we have made to comprehensively search the related studies, some information might have been missed. Second, between-study heterogeneity existed in the current meta-analysis. Although sensitivity analysis and subgroup analysis were applied to find the source of heterogeneity, some heterogeneity couldn't be fully explained by statistical methods. Clinical heterogeneity might play a role in the large between-study heterogeneity, such as disease stage and age. Third, three genotypic models (heterozygote variant vs. wild type, homozygote variant vs. wild type and the dominant model) were used for this study, the other models including recessive model and allele comparison were not performed because of limited raw data. However, the models used in the study were commonly used in genetic analysis, and could in part decrease the type I error inflation^[@CR135]^. Fourth, we didn't analyze the role of gene-gene as well as gene-environment interactions in the modification of chemotherapy efficacy, and attention should be paid to these factors in further studies.

In conclusion, this collection of data might provide a useful platform for research and clinical healthy practice. Further work still needs to be done to pinpoint the use of these SNPs as prognostic biomarkers for assessing objective response and progression risk in NSCLC patients receiving platinum-based regimens.
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